🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "major milestone" in the battle against superbug strains of the pathogen, according to researchers.

A Worldwide Public Health Issue

Cases of gonorrhoea are on the rise around the world, with data suggesting in excess of 82 million new cases each year. Notably increased rates are seen in Africa and countries within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. Within England, cases have reached a historical peak, while rates across Europe in 2023 were three times higher compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune advancement in the context of rising global incidence, the spread of superbugs and the highly restricted treatment choices presently on offer.”

Health officials are particularly alarmed about the increase in drug-resistant strains. The WHO has classified it as a "priority pathogen". Recent surveillance showed that the effectiveness of primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Receive Approval

Zoliflodacin, marketed under the name Nuzolvence, was approved by the US Food and Drug Administration in recent days for use against gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Scientists believe that targeted use of this new drug will help hinder the development of resistance.

Another new antibiotic, created by the drugmaker GSK, also received approval in close succession. This medication, which is employed against UTIs, was shown in trials to be successful in treating superbug versions of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin emerged from a new, not-for-profit approach for medication research. The non-profit organisation GARDP partnered with the drug firm its industry partner to see it through.

“This milestone signifies a major breakthrough in the treatment of superbug gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Clinical Trial Outcomes and Worldwide Availability

Based on results published in a prominent scientific publication, the new drug successfully treated more than 90% of genital gonorrhoea infections. This places it at an equal footing with the existing first-line therapy, which involves a dual-drug approach. The research enrolled hundreds of participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the authority to license and sell the drug in numerous regions with limited resources.

Clinicians treating patients have shared optimism. The availability of a easy-to-administer therapy such as this is hailed as a "game-changer" for gonorrhoea control. This is deemed crucial to reduce the burden of the disease for people and to stop the proliferation of highly drug-resistant gonorrhoea around the world.